GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD.

Guangdong Taienkang Pharmaceutical Co., Ltd.

301263

CNE1000058X0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-20 pm EDT			5-day change	1st Jan Change
12.93 ^CNY	+1.25%		+0.15%	-20.82%

May. 14	Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	CI
Apr. 22	Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BCY Pharm Co., Ltd. announced that it has received CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd

September 06, 2023

On September 7, 2023, BCY Pharm Co., Ltd. closed the transaction. The company's registered capital is CNY 36,616,250.

Latest news about Guangdong Taienkang Pharmaceutical Co., Ltd.

Guangdong Taienkang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023	May. 14	CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Guangdong Taienkang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 22	CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023.	Apr. 01	CI
Tranche Update on Guangdong Taienkang Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 31, 2023.	Jan. 02	CI
Guangdong Taienkang Pharmaceutical Co., Ltd announces an Equity Buyback for CNY 50 million worth of its shares.	23-10-31	CI
Guangdong Taienkang Pharmaceutical Co., Ltd authorizes a Buyback Plan.	23-10-30	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Guangdong Taienkang Pharmaceutical Co., Ltd(XSEC:301263) added to S&P Global BMI Index	23-09-18	CI
BCY Pharm Co., Ltd. announced that it has received CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd	23-09-06	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
BCY Pharm Co., Ltd. announced that it expects to receive CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd	23-08-24	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend on A Shares for the Year 2022, Payable on 29 May 2023	23-05-19	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for 2022	23-04-27	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-26	CI
Certain A Shares of Guangdong Taienkang Pharmaceutical Co., Ltd are subject to a Lock-Up Agreement Ending on 30-MAR-2023.	23-03-29	CI
Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan	23-02-20	MT
Guangdong Taienkang Pharma to Buy 50% of Local Biomedical Firm For 200 Million Yuan	23-02-15	MT
Guangdong Taienkang Pharmaceutical Co., Ltd entered into an investment agreement to acquire BCY Pharm Co., Ltd from Nanjing Baijiahui Biotechnology Development Co., Ltd and others for CNY 200 million.	23-02-13	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Guangdong Taienkang Pharmaceutical Announces A 2021 Final Profit Distribution Payable on 30 May 2022	22-05-24	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Approves Cash Dividend for 2021	22-05-19	CI
Guangdong Taienkang Pharmaceutical Co., Ltd Proposes Final Cash Dividend for the Year 2021	22-04-27	CI

Chart Guangdong Taienkang Pharmaceutical Co., Ltd.

Duration

Period

Chart Guangdong Taienkang Pharmaceutical Co., Ltd.

More charts

Guangdong Taienkang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development and production of pharmaceutical products. The Company's businesses include agency operation, and sales of pharmaceutical products, medical devices and hygiene materials. The Company's main products include chemical medicines, external medicines, proprietary Chinese medicines, medical devices and hygiene materials. The Company is also engaged in the provision of medical technology services and technology transfer. The Company mainly conducts its businesses in the domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD.	-20.82%	754M
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+41.51%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.66%	244B
ROCHE HOLDING AG	+3.39%	228B
NOVARTIS AG	+10.75%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals

Guangdong Taienkang Pharmaceutical Co., Ltd.

Equities

301263

CNE1000058X0

Pharmaceuticals

BCY Pharm Co., Ltd. announced that it has received CNY 150 million in funding from Guangdong Taienkang Pharmaceutical Co., Ltd

Latest news about Guangdong Taienkang Pharmaceutical Co., Ltd.

Chart Guangdong Taienkang Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals